Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 40Lymphoma, Non-Hodgkin 39Lymphoma, Follicular 24Lymphoma 22Lymphoma, Large B-Cell, Diffuse 19Lymphoma, Mantle-Cell 18Lymphoma, B-Cell 10Recurrence 9Neoplasms 8Lymphoma, B-Cell, Marginal Zone 8Leukemia 6Hodgkin Disease 6Multiple Myeloma 4Hematologic Diseases 4Lymphoma, T-Cell, Peripheral 3Advanced Solid Tumor 2Waldenstrom Macroglobulinemia 1Tumor Lysis Syndrome 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Lymphoproliferative Disorders 1Lymphatic Diseases 1

Interventions

Temozolomide 3Irinotecan 3tozuleristide 2selpercatinib 2lenvatinib 2gadobenic acid 2avelumab 2Radiation 2Paclitaxel 2Leflunomide 2Immunotherapy 2Gemcitabine 2Everolimus 2Cisplatin 2Carboplatin 2Cancer Vaccines 2Bevacizumab 2Adjuvants, Immunologic 2ridaforolimus 1regorafenib 1prinomastat 1pomalidomide 1perillyl alcohol 1pemigatinib 1pembrolizumab 1pamiparib 1omburtamab I-131 1irinotecan sucrosofate 1interferon gamma-1b 1infigratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Central Nervous System Neoplasms × Bendamustine Hydrochloride × Clear all
NCT04792489 2025-04-24

DALY II USA/ MB-CART2019.1 for DLBCL

Miltenyi Biomedicine GmbH

Phase 2 Recruiting
248 enrolled
CNSLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡